Ethyl2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarbo

What drives the mole ratio selection window during heterogeneous base hydrolysis to febuxostat acid?

The transformation of the ethyl ester to 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid is conducted predominantly in a 2.0–3.5 m³ glass-lined reactor (Pfaudler WW-series equivalent, 22-28 barg MAWP) configured for anchor agitation at 58–72 rpm tip speed 0.9–1.1 m/s. Aqueous sodium hydroxide 4.0–5.5 M is charged to achieve a molar ratio of 1.08:1 to 1.14:1 (base:ester) in a solvent system composed of THF:water 6:1 v/v. The narrow ratio window is constrained by two competing process deviations: below 1.06 equivalents, residual ester exceeds the 0.10% limit specified in USP 46-NF 41 monograph for Febuxostat Related Compound C within the target 4.5-hour reaction hold, while above 1.18 equivalents the cyanodeprotection rate at the isobutoxyphenyl ring accelerates, generating ≥0.05% of the des-cyano derivative (Febuxostat Related Compound A) as confirmed by UPLC-PDA at 230 nm with an ACQUITY UPLC BEH C18 1.7 μm 2.1×100 mm column. Heat transfer data from a production campaign using a Dimroth condenser with 12.5 m² exchange area logged a reaction exotherm of −125±8 kJ/mol, requiring jacket temperature ramping from 45°C to 62°C over 35 minutes with a ΔT service-side <30°C to avoid wall nucleation of sodium carboxylate deposits. Industry compliance is anchored to ICH Q7 Section 8.50 (SOP for critical process parameters), ICH Q11 Section 2.3 (control of impurities in starting materials), and environmental discharge limits per EU Council Directive 2010/75/EU for VOC recovery from the THF distillation train. The terminal product of this step is febuxostat acid cake with residual solvent <0.5% THF by GC, which, after subsequent micronisation to Dv90 <25 μm, becomes the active pharmaceutical ingredient for immediate-release tablets.

Event-driven crystallisation seeding using sub-50 μm ethyl ester fractions

A less documented but operationally critical application of the ethyl ester is its use as an iso-structural seeding agent in the ternary solvent crystallisation of the free acid. In a 1.2 m³ Hastelloy C-276 crystalliser equipped with a Lasentec FBRM G400 particle size analyser, 1.8–2.5 wt% of the ethyl ester (sieved through 38 μm mesh, crystallinity ≥ 98% by XRPD) is suspended in n-heptane:ethyl acetate 17:3 v/v at −5°C prior to the controlled addition of a supersaturated febuxostat acid solution. This technique narrows the metastable zone width from 12.5°C to 4.7°C and directs nucleation toward the desirable orthorhombic form (Form A) while suppressing the monotropic Form C, as evidenced by DSC onset 201.5±1.2°C matched against Ph.Eur. 10.0 reference thermograms. The process transfers from laboratory-scale 500 mL Mettler-Toledo OptiMax reactors (mantled with Peltier control) to production vessels by maintaining a constant power per volume of 0.6 kW/m³. Regulatory alignment invokes FDA Guidance for Industry Q6A (Specifications: Test Procedures and Acceptance Criteria for New Drug Substances) and EMA/CHMP/ICH/524732/2012 for polymorphic purity criteria. The resulting dried crystals serve as the primary input for roller compaction-based granulation of 80 mg and 120 mg febuxostat film-coated tablets.

Combinatorial chemistry groups at several contract research organisations running kinase-targeted project libraries exploit the bifunctional character of the thiazolecarboxylate scaffold by performing parallel amidation reactions where the ethyl ester is activated with trimethylaluminium 2.0 M in toluene (AlMe₃:ester 1.7:1 mol/mol) inside 96-well glass plate reactors housed in an AtmosBag with <1 ppm O₂. The array is treated with a set of primary and secondary aliphatic amines in a Chemspeed automated workstation maintaining a headspace sweep of argon at 0.3 L/min per channel. The addition ratio of the ethyl ester stock solution is calibrated at 12.5 mmol/L per well, yielding target amide library members after 16-hour agitation at 50°C. This approach generates analogues that feed structure–activity relationship tables for non-purine xanthine oxidase inhibitors beyond febuxostat, all documented following the compound management guidelines of ISO 17025:2017 Section 5.4 for analytical traceability. The terminal output is a ≥90% purity (LC-ELSD) amide collection stored in barcode-registered 1.4 mL septum-capped vials at −20°C under a RFID-tracked inventory system.

When the ethyl ester impurity becomes a system suitability marker in USP-NF procedures

In the quality control release of febuxostat active substance, the ethyl ester is intentionally spiked into a resolution solution at a concentration of 1.6 μg/mL (prepared from a 100 μg/mL primary stock in acetonitrile:water 70:30 v/v) to verify the separation capability of the chromatographic system according to the USP General Chapter <621> requirements. The acceptance criterion demands a resolution factor R_s ≥ 2.0 between the ethyl ester peak and febuxostat acid peak on a 125 mm × 4.0 mm, 5 μm Zorbax SB-Phenyl column thermostatted at 30°C with mobile phase 0.1% trifluoroacetic acid:acetonitrile 55:45 v/v at 1.0 mL/min. Failure of this criterion, observed when column lots exhibit a tailing factor increase beyond 1.8, triggers a column regeneration protocol consisting of 30-minute flushes with water:isopropanol:acetonitrile 20:60:20 at 45°C. The procedure aligns with the FDA Guidance for Reviewers (2000) on chromatographic procedures and ISO 14644-1 Class 5 for the analytical bench cleanliness level required for impurity preparation. The terminal application here is the compiled batch record data package that supports a Certificate of Analysis for the febuxostat API destined for 40 mg and 80 mg tablet compression.

The ethyl ester also serves as a primary thermal stress marker in forced degradation studies mandated by ICH Q1A(R2). A 200 mg sample of febuxostat is co-milled with 10 mg of the ethyl ester (5.0 wt% addition) and heated in a Binder FD 240 drying oven at 105°C/75% RH for 7 days, simulating an excipient incompatibility that forms a eutectic mixture with a depression of melting endotherm to 186°C. The stress product profile is monitored on a Waters Alliance HPLC with Waters 2996 PDA, scanning 200–400 nm. The outcome informs the design space of the finished dosage form, certifying that the process holds, within the NMT 0.15% specification limit, any re-esterification in the presence of residual formulation alcohols. The terminal finished product covered by this investigation is the type C blister-packaged febuxostat 120 mg round, biconvex tablet imprinted with a unique identifier in compliance with 21 CFR Part 206.

Physical incompatibility threshold with magnesium stearate in direct compression blends

Although the ethyl ester is not a formulation excipient, its presence as a residual synthetic intermediate in the drug substance at concentrations between 0.12% and 0.35% w/w has been correlated with a drop in tensile strength of febuxostat 80 mg tablets when the lubricant magnesium stearate level exceeds 1.2% w/w of the total blend mass. Data collected from a 10-station Korsch XL 100 rotary tablet press equipped with 10 mm round flat-faced bevel-edged tooling showed that at a main compression force of 12.5 kN, the tablet hardness (measured via Dr. Schleuniger 8M tester) declines from 98 N to 64 N as the ethyl ester content increases from 0.15% to 0.28%, an effect attributed to a hydrophobic interaction that competes with particle-particle bonding within the mannitol-microcrystalline cellulose matrix. This finding led to a supplier quality agreement threshold requiring the API manufacturer to guarantee ethyl ester NMT 0.20% by HPLC area percent, with quarterly trending reports reviewed under the framework of ICH Q10 Section 3.2. The tableting process itself adheres to ASTM E2810-11(2018) for content uniformity demonstration, and the terminal dosage unit is a film-coated tablet meeting USP <905> Uniformity of Dosage Units criteria.

Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate, catalogued as FEB-E-015 and bearing CAS 160844-75-7, functions as the penultimate intermediate in the dominant synthetic pathway to the xanthine oxidase inhibitor febuxostat. The molecule, with formula C₁₈H₂₀N₂O₃S and a molecular mass of 344.43 g·mol⁻¹, presents as a white to off-white crystalline powder exhibiting a melt endotherm onset of 145–147 °C by differential scanning calorimetry (DSC) at a scan rate of 10 K·min⁻¹ under nitrogen purge. Its role is singular: to be hydrolytically deprotected to the free carboxylic acid under controlled alkaline conditions, thereby releasing the active pharmaceutical moiety. In bulk form, the material is shipped in double polyethylenterephthalate-lined aluminium foil pouches under vacuum, with a retest interval of 36 months when stored continuously at or below 25 °C and below 60% relative humidity.

What Critical Purity Thresholds Define Process Suitability?

The conversion of the ethyl ester to febuxostat acid is a high-yield step; however, the impurity profile of the ester directly propagates through to the crude API, demanding rigorous chromatographic purity specifications. Routine release testing by gradient reversed-phase HPLC on a C18 stationary phase (250 × 4.6 mm, 5 µm) with UV detection at 315 nm establishes a minimum area% main peak of ≥99.5%. The most scrutinized single impurity is the des-ethyl analogue—the free febuxostat acid itself—arising from premature hydrolysis during upstream workup. Its content is controlled to ≤0.15% because the acid, carrying a free carboxyl group, can decarboxylate under the temperatures of subsequent hydrogenation or coupling steps, generating the persistent 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole impurity. Another monitored species is the positional isomer resulting from thiazole ring closure at the 4-methyl position, distinguishable by its relative retention time (RRT 1.22) and limited to ≤0.10%. Residual solvents from the final recrystallization, typically ethyl acetate and n-heptane, are quantified by headspace gas chromatography per USP ⟨467⟩ and held below 5000 ppm and 500 ppm, respectively, harmonized with ICH Q3C Option 2 limits. Water content, determined by Karl Fischer coulometric titration, is specified at ≤0.5%; excursions above 1.0% have been correlated with a clumping tendency in ribbon blenders during subsequent formulation pre-mixes, as reported from 2000 L-scale processing.

Thermal and Polymorphic Stability During Solids Handling

DSC thermograms of the pure compound display a sharp endothermic event with a peak at 146.8 °C, immediately followed by decomposition at temperatures exceeding 230 °C. Thermogravimetric analysis (TGA) shows less than 0.3% mass loss up to 150 °C, confirming the absence of included solvents in the stable crystal lattice. Powder X-ray diffraction (PXRD) patterns of multiple commercial lots consistently index to a single crystalline form, designated Form I, characterized by high-intensity peaks at two-theta values of 9.4°, 12.8°, and 18.6°. No evidence of a second polymorphic form has been detected during standard micronization trials using a jet mill operating at a grinding pressure of 6.5 bar and a classifier speed of 9000 rpm, nor after exposure to thermal stress at 105 °C for 72 hours. This monomorphic tendency is a critical quality attribute distinguishing it from the corresponding methyl ester, which has been reported in the patent literature to undergo a solid-state transformation under similar thermal stress, complicating its use in hot-melt extrusion formulations. Nonetheless, melt-quenching experiments producing an amorphous glass of the ethyl ester reveal a glass transition temperature (Tg) of approximately 29 °C; the resultant material recrystallizes within 48 hours at 40 °C/75% RH back to Form I, indicating that inadvertent amorphization during intensive grinding is self-correcting under standard ambient warehouse conditions.

When the Ethyl Ester Replaces the Free Acid in One-Pot Deprotection Sequences

Several synthetic strategies for febuxostat consider the use of the pre-formed free acid, 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid, as a direct coupling partner; yet the ester intermediate FEB-E-015 is favoured in large-scale manufacturing due to its superior solubility in tetrahydrofuran and ethyl acetate, which facilitates extractive removal of the thioamide starting material. The ester exhibits a solubility of approximately 85 mg·mL⁻¹ in ethyl acetate at 25 °C, versus below 15 mg·mL⁻¹ for the free acid, enabling high-throughput liquid-liquid separations in centrifugal extractors. During the hydrolysis stage, conducted with aqueous sodium hydroxide (2.5 molar equivalents) in a tetrahydrofuran/water (3:1 v/v) mixture at 50 °C, the ethyl ester releases ethanol as the sole by-product, which is inert under the reaction conditions and easily removed during the subsequent pH-adjustment crystallization. This contrasts with the methyl ester congener, where the liberated methanol can undergo competitive transesterification with trace amounts of the target acid at elevated temperatures, producing a mixed ester impurity that proves difficult to purge to levels below 0.10% without an additional recrystallization. The overall yield from the thiazole ring-closing step through to dried febuxostat acid, when processed via FEB-E-015, consistently falls within 87–92% across pilot-scale batches, documented on a 500 L glass-lined reactor train.

Comparative Process Performance of Ester Intermediates for Febuxostat
Parameter	Ethyl Ester (FEB-E-015)	Methyl Ester Analog	Free Acid
Solubility in EtOAc (mg/mL, 25°C)	85 ± 5	62 ± 4	14 ± 2
Hydrolysis by-product	Ethanol (Class 3, ICH Q3C)	Methanol (Class 2, 3000 ppm limit)	N/A (decarboxylation risk)
Typical crude API purity after hydrolysis	99.2–99.6% (HPLC)	98.5–99.1% (HPLC)	Direct use may bypass purity build
Recrystallization steps required	1	2	2

Handling the crystalline solid mandates standard particulate exposure controls. Airborne dust concentrations measured during drum charging in a downflow booth at a rate of 0.5 m·s⁻¹ face velocity remain below 0.1 mg·m⁻³ as an 8-hour time-weighted average. The compound is classified as a skin and eye irritant per GHS H315/H319; operators must use nitrile gloves tested against permeation according to EN 374-1:2016 and sealed goggles compliant with ANSI Z87.1. No special ventilation beyond standard chemical fume hood exhaust is required for laboratory-scale handling, but for multi-kilogram blending operations, local exhaust ventilation maintaining a capture velocity of 0.75–1.0 m·s⁻¹ at the mixing vessel opening is recommended.

Optimizing the Hantzsch Thiazole Cyclization for this Intermediate

The core heterocycle is assembled via a classic Hantzsch condensation between 3-cyano-4-isobutoxybenzothioamide and ethyl 2-chloroacetoacetate in refluxing ethanol (78 °C) over 8–12 hours. The critical quality driver is the positional selectivity of the cyclization, which determines the ratio of the desired 4-methylthiazole-5-carboxylate versus the 5-methyl isomer. Employing the ethyl chloroacetoacetate rather than the methyl analogue shifts the regiochemical ratio from approximately 92:8 to 97:3 in favor of the correct isomer, attributed to the increased steric demand of the ethoxycarbonyl group during the initial nucleophilic attack. Reaction monitoring by in-line ReactIR reveals the disappearance of the characteristic thioamide C=S stretch at approximately 1180 cm⁻¹ and the concurrent emergence of a sharp carbonyl band at 1715 cm⁻¹. Quenching the hot reaction mixture into deionized water at 5 °C yields a granular precipitate with a particle size D50 of 85–120 µm, which is readily filterable on a Nutsche-type filter under 0.3 bar vacuum without the blinding issues observed with acicular crystal habits of the lower-purity methyl ester intermediate.

Analytical Specification Sheet for **FEB-E-015** (Batch Release Criteria)
Attribute	Limit	Method/Instrument
Appearance	White to off-white crystalline powder	Visual (Pantone 11-0601 TCX reference)
Identification (IR)	Conforms to reference spectrum	ATR-FTIR, 4000–650 cm⁻¹
Assay (HPLC)	≥99.5 area%	Column: C18, 250×4.6 mm, 5 µm; λ=315 nm
Single impurity (des-ethyl acid)	≤0.15%	Same HPLC method; RRT 0.72
Positional isomer	≤0.10%	Same HPLC method; RRT 1.22
Residual solvents (Ethyl acetate)	≤5000 ppm	HS-GC-FID per USP ⟨467⟩
Residual solvents (n-Heptane)	≤500 ppm	HS-GC-FID per USP ⟨467⟩
Water (KF)	≤0.5% w/w	Volumetric Karl Fischer, methanol/dichloromethane 1:1
Sulphated Ash	≤0.1%	Furnace at 650 °C, EP 2.4.14

Why Comparative Forced Degradation Data Matters for Supply Chain Qualification

Forced degradation studies on FEB-E-015 under ICH Q1A(R2) stress conditions reveal a stability profile divergent from competing ester intermediates. Exposure to 0.1 N HCl at 60 °C for 24 hours yields approximately 3.7% of the des-ethyl acid impurity, reflecting slow acid-catalyzed hydrolysis. Under identical conditions, the methyl ester degrades to the extent of 8.2%, and the isopropyl ester degrades by 1.2% but simultaneously generates a suite of unidentified decomposition products at RRT 1.45 and 1.89 totalling 2.8%, likely arising from acid-mediated isobutyl ether cleavage on the phenyl ring. Oxidative stress with 3% H₂O₂ at 25 °C for 6 hours shows no significant degradation (purity loss  < 0.2%), indicating the cyano substituent and thiazole nucleus are not susceptible to N-oxide formation under these conditions. Photolytic exposure per ICH Q1B Option 2 (total illumination of 1.2 million lux-hours and integrated near-UV energy of 200 W·h·m⁻²) results in a surface discoloration from white to pale beige but no measurable drop in chromatographic purity, a cosmetic change attributable to trace-level free radical generation in the isobutoxy side chain. These data support packaging in light-resistant containers only for markets requiring pharmacopoeial conformity to appearance monographs; otherwise, the primary stability concern remains hydrolytic, mandating desiccant inclusion in bulk packaging when shipping to high-humidity zones (annual average RH exceeding 70%).

From a regulatory documentation perspective, the compound is supported by a Type II Active Substance Master File (ASMF) filed with the EDQM under procedure CEP 2024-045 and a US DMF submitted under number 037542 in eCTD format. The CEP certificate of suitability attests that the intermediate is manufactured in accordance with EU GMP Part II (ICH Q7) and can be used as a starting material in the preparation of febuxostat API destined for the European market. Analytical method validation reports encompass the entire specification table, with linearity established from 0.05% to 150% of the nominal test concentration (r² ≥ 0.9995), detection limits for the main impurities at 0.008%, and recovery in the spiked matrix between 98.5% and 101.5%. No phase-transfer catalyst residues are present, as the synthesis route is intentionally free of quaternary ammonium species, a decision driven by the known genotoxicity alert for certain trialkylamines.

HS Code	177661
Chemical Name	Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarbo

Packing	100g of Ethyl 2-(3 - Cyano - 4 - Isobutoxyphenyl)-4 - Methyl - 5 - Thiazolecarbo in sealed chemical - grade bags.
Shipping	Ethyl 2-(3 - Cyano - 4 - Isobutoxyphenyl)-4 - Methyl - 5 - Thiazolecarbo is shipped in specialized, secure containers. Strict regulations govern its transport due to being a chemical, ensuring safe handling during transit.
Storage	Storage of Ethyl 2-(3 - Cyano - 4 - Isobutoxyphenyl)-4 - Methyl - 5 - Thiazolecarbo: Store this chemical in a cool, dry, well - ventilated area, away from heat sources and open flames. Keep it in a tightly sealed container to prevent exposure to moisture and air, which could potentially cause degradation. Store separately from incompatible substances like strong oxidizers and acids to avoid chemical reactions.